{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T04:21:11Z","timestamp":1744258871616,"version":"3.40.4"},"reference-count":10,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"2","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Alerg Mex"],"abstract":"<jats:p>Background: The Pfizer-BioNTech BNT162b2 vaccine, provides 95% effectiveness from the second dose onwards. The reported rate of anaphylaxis to COVID-19 vaccines is 4.7 cases\/million doses administered. Case presentation: 30-year-old female, health professional, history of allergic rhinitis, asthma, reaction to eye cosmetics and adhesive tape: erythema, edema and local pruritus. Immediately after application of the first dose of Pfizer-BioNTech vaccine, she presented grade III anaphylaxis. The patient was stratified, phenotyped and skin tests with PEG 3350 were positive. A recommendation was issued not to reapply vaccine containing polyethylene glycol and alternatives were offered. Discussion: An adequate risk stratification should be performed before applying mRNA-based COVID-19 vaccines for the first time in at-risk groups. In case of anaphylaxis at the first dose, phenotyping and further study with PEG skin tests should be performed and vaccination alternatives should be offered.<\/jats:p>","DOI":"10.29262\/ram.v69i2.1088","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T05:04:02Z","timestamp":1672895042000},"page":"89-92","source":"Crossref","is-referenced-by-count":0,"title":["Alergia a la vacuna Pfizer-BioNTech\u00ae demostrada mediante pruebas cut\u00e1neas","Allergy to Pfizer-BioNTech vaccine demonstrated by skin testing"],"prefix":"10.29262","volume":"69","author":[{"given":"Carlos David","family":"Estrada Garc\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Paola","family":"Mac\u00edas Robles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa Mar\u00eda","family":"Cort\u00e9s Grimaldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilda Lilian","family":"Carvajal Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlen","family":"Barreto Alcal\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Ram\u00edrez Nepomuceno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Esparza Amaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kareli Guadalupe","family":"Coronado Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britza","family":"Barrios D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9ctor Hugo","family":"Campos T\u00e9llez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"54418","unstructured":"World Health Organization. WHO Coronavirus (COVID-19) Dashboard [Internet]. 2022 [citado el 20 de enero de 2022]. Disponible en: https:\/\/covid19.who.int\/info\/"},{"key":"54419","doi-asserted-by":"crossref","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N Engl J Med 2020;383(27):2603-2615. DOI: 10.1056\/NEJMoa2034577.","DOI":"10.1056\/NEJMoa2034577"},{"key":"54420","unstructured":"Oliver S. Updates to the Evidence to Recommendation Framework: Pfizer-BioNTech and Moderna COVID-19 vaccine booster doses. Disponible en: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/slides-2021-09-22-23.html"},{"key":"54421","doi-asserted-by":"crossref","unstructured":"Shimabukuro T, Nair N. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine. J Am Med Assoc 2021;325(8):780-781. Disponible en: https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2775646","DOI":"10.1001\/jama.2021.0600"},{"key":"54422","doi-asserted-by":"crossref","unstructured":"Rutkowski K, Mirakian R, Till S, et al. Adverse reactions to COVID-19 vaccines: A practical approach. Clin Exp Allergy. John Wiley and Sons Inc 2021; Vol. 51:770\u2013777. DOI: 10.1111\/cea.13880.","DOI":"10.1111\/cea.13880"},{"key":"54423","doi-asserted-by":"crossref","unstructured":"Turner PJ, Ansotegui IJ, Campbell DE, et al. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organ J. Elsevier Inc 2021;Vol. 14(2): 100517. DOI: 10.1016\/j.waojou.2021.100517","DOI":"10.1016\/j.waojou.2021.100517"},{"key":"54424","doi-asserted-by":"crossref","unstructured":"Moghimi SM. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines., Mol Ther. Cell Press 2021;Vol. 29:898\u2013900. DOI: 10.1016\/j.ymthe.2021.01.030","DOI":"10.1016\/j.ymthe.2021.01.030"},{"key":"54425","doi-asserted-by":"crossref","unstructured":"Stone CA, Liu Y, Relling MV, et al. Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized. J Allergy Clin Immunol: In Practice 2019;7(5):1533-1540.e8. DOI: 10.1016\/j.jaip.2018.12.003","DOI":"10.1016\/j.jaip.2018.12.003"},{"key":"54426","doi-asserted-by":"crossref","unstructured":"Banerji A, Wickner PG, Saff R, et al. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. J Allergy Clin Immunol Pract. American Academy of Allergy, Asthma and Immunology 2021;Vol. 9:1423\u20131437. DOI: 10.1016\/j.jaip.2020.12.047","DOI":"10.1016\/j.jaip.2020.12.047"},{"key":"54427","doi-asserted-by":"crossref","unstructured":"Kelso JM. Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines. Ann Allergy Asthma Immunol 2021;127(1):133\u2013134. Disponible en: http:\/\/www.annallergy.org\/article\/S108112062100257X\/fulltext","DOI":"10.1016\/j.anai.2021.03.024"}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1088\/1997","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1088\/2710","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1088\/2709","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1088\/1997","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:18:00Z","timestamp":1744215480000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/1088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,4,24]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v69i2.1088","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"type":"electronic","value":"2448-9190"},{"type":"print","value":"0002-5151"}],"subject":[],"published":{"date-parts":[[2023,5,31]]}}}